Nutritional Strategies to Augment the Postprandial Muscle Protein Synthetic Response to the Ingestion of a Low Dose of Protein in Middle-aged Women

Aging Clinical Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02918981
• Other study ID #: 16999
• Status: Completed
• Phase: N/A
• Start date: October 2016
• Est. completion date: March 6, 2019

Study information

• Verified date: November 2020
• Source: University of Illinois at Urbana-Champaign
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Using stable isotope methodology, investigators will determine the postabsorptive and postprandial muscle protein synthetic response in 60 female adults (Age 50-79, BMI: <30 kg/m2) immediately after an acute bout of resistance exercise. Participants will be divided in to 5 groups of twelve women (n=12). Each group will receive a different protein beverage or placebo to consume following the resistance exercise training. Group 1 will consume a beverage consisting of whey protein; group 2 will consume whey protein supplemented with additional leucine; group 3 will consume whey protein supplemented with additional leucine and hydrolyzed whey peptides; group 4 will consume whey protein supplemented with additional leucine and citrulline; group 5 will just consume water. During the testing, blood and muscle samples will be collected.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 50
• Est. completion date: March 6, 2019
• Est. primary completion date: March 6, 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 20 Years to 79 Years

Eligibility

Inclusion Criteria:

• BMI <30 kg/m2

• Healthy, sedentary

• Either 20-30 years old or 50-79 years old

Exclusion Criteria:

• Tobacco use

• Allergies to milk consumption

• Unusually high protein consumption

• Vegan diet

• Allergies to antibiotics or xylocaine

• Phenylketonuria (PKU)

• Diagnosed GI tract diseases

• Arthritic conditions

• A history of neuromuscular problems

• Heart disease

• Metabolic disorders

• -Liver, kidney, or urinary disease

• Musculoskeletal problems

• Autoimmune disease

• Neurological disease

• Previous participation in amino acid tracer studies

• Predisposition to hypertrophic scarring or keloid formation

• Individuals on any medications known to affect protein metabolism (i.e. corticosteroids, non-steroidal anti-inflammatories, or prescription strength acne medications).

• Individuals using thyroid medications or other medications affecting endocrine function

• Pregnancy

• Contraindications for exercise

• BMI =30

• supplements that influence protein metabolism (e.g omega 3 fish oils)

Related Conditions & MeSH terms

• Aging

Intervention

Behavioral:
• Resistance Exercise
Participants will perform unilateral leg extension exercise immediately prior to ingestion of the experimental beverage

Dietary Supplement:
• 14 g Whey protein

• 6.6 g Whey protein + 1.25 g leucine

• 4 g Whey protein + 1.25 g leucine + 2.6 g Whey peptides

• 6.6 g Whey protein + 1.25 g leucine + 0.8 g Citrulline

Other:
• Water control

Locations

Country	Name	City	State
United States	Freer Hall	Urbana	Illinois

Sponsors (1)

Lead Sponsor	Collaborator
University of Illinois at Urbana-Champaign

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The myofibrillar protein synthetic response to protein ingestion	Myofibrillar protein synthesis rates will be assessed during the postabsorptive period for 3 hr and during the 4 hr after the ingestion of the experimental beverages. This will allow us to assess the change from the postabsorptive to the postprandial period	Postabsorptive for 3 hours, Postprandial for 4 hours hours
Secondary	mTORC1 phosphorylation	Activation of anabolic signaling pathways will be assessed in the fasted state and at 2 and 4 hr after the ingestion of the experimental beverages.	Baseline and at 2 and 4 hours after protein ingestion